VJHemOnc is committed to improving our service to you

SOHO Italy 2020 | Novel approaches to PV and ET

VJHemOnc is committed to improving our service to you

Alessandro Lucchesi

Alessandro Lucchesi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses novel therapies for polycythemia vera (PV) and essential thrombocythemia (ET) including ropeginteferon, an interferon that has been shown to control hematocrit levels in PV as evaluated in the CYTO-PV study. Dr Lucchesi outlines unmet clinical needs in this patient population including controlling the rate of thrombosis and reducing transformation into severe disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter